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Effect of Diet or Diet Plus Physical Activity Versus Usual Care on
InflammatoryMarkers inPatientswithNewlyDiagnosedType2Diabetes:
The Early ACTivity In Diabetes (ACTID) Randomized, Controlled Trial
Dylan Thompson, PhD; Jean-Philippe Walhin, PhD; Alan M. Batterham, PhD; Keith A. Stokes, PhD; Ashley R. Cooper, PhD;
Robert C. Andrews, MBChB, PhD
Background-—Inflammation plays a major role in diabetes-associated cardiovascular disease (CVD). There is uncertainty whether
diet and physical activity interventions can be successfully integrated into healthcare settings and reduce markers of inflammation
and risk of CVD in patients with type 2 diabetes (T2D).
Methods and Results-—Systemic markers of inflammation were determined in a 12-month, real-world, multicenter, randomized,
controlled trial that investigated the effect of diet, diet plus physical activity, and usual care in 593 individuals with newly diagnosed
T2D. During the first 6 months, serum C-reactive protein (CRP) improved by 21 (36 to 1.4)% and 22 (38 to 3.1)% in diet
and diet plus physical activity arms versus usual care. There were also improvements in adiponectin and soluble intercellular
adhesion molecule-1 (sICAM-1). Though medication-adjusted CRP was improved between 6 and 12 months for usual care, both
interventions were more successful in reducing the relative risk of a high-risk CRP level of >3 mg/L (risk ratios of 0.72 [0.55 to
0.95] for diet versus usual care and 0.67 [0.50 to 0.90] for diet plus activity versus usual care). Furthermore, sICAM-1 (a marker of
vascular risk), remained substantially lower than usual care in both intervention arms at 12 months.
Conclusions-—Motivational, unsupervised diet and/or diet plus physical activity interventions given soon after diagnosis in real-
world healthcare settings improve markers of inflammation and cardiovascular risk in patients with T2D, even after accounting for
the effect of adjustments to medication to try and control blood pressure, glycated hemoglobin, and lipids.
Clinical Trial Registration-—URL: http://www.controlled-trials.com/. Unique identifier: ISRCTN92162869. ( J Am Heart Assoc.
2014;3:e000828 doi: 10.1161/JAHA.114.000828)
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S ystemic markers of low-grade inflammation representan important adjunct to the capture of conventional
cardiovascular risk factors.1 Of the measures that are readily
available, high-sensitivity serum concentration of C-reactive
protein (CRP) is the most widely used and appears to have
consistent predictive value in various populations and groups.
Individuals with a CRP level of greater than 3 mg/L are
considered at high risk of cardiovascular disease (CVD).1
People with type 2 diabetes (T2D) tend to have higher
markers of inflammation, and circulating CRP concentrations
increase continuously across the spectrum of fasting glucose
concentrations beginning at the lowest quartile of normal
fasting glucose.2 In patients with type 2 diabetes, CRP is an
independent risk factor for cardiovascular events,3,4 risk of
death,5 atherosclerotic progression,6 and development of
peripheral vascular disease.7
Increased physical activity and dietary advice implemented
by healthcare professionals is recommended by international
consensus in the management of T2D.8 The effect of diet
and/or physical activity on inflammation-associated cardio-
vascular risk in patients with T2D has been poorly character-
ized. Of the studies that exist, most represent small efficacy
trials involving only a handful of patients and with the
investment of significant resources to support lifestyle
changes (eg, supervision of exercise). These small studies
confirm that intensive interventions designed to reduce
weight and/or increase participation in supervised exercise
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can lead to profound beneficial effects on inflammatory
markers in people with T2D (eg, as reported previously9–11).
One larger study confirmed that carefully supervised exercise
reduces CRP in people with T2D.12 However, the relevance of
these findings for clinical care are uncertain, given that the
provision of supervised physical activity will be unlikely in
most healthcare settings because of resources that would be
required. The Look AHEAD study recently demonstrated that
an intensive lifestyle intervention consisting of unsupervised
physical activity combined with dietary advice can reduce CRP
in people with T2D.13 Notably, although the exercise compo-
nent in Look AHEAD was unsupervised, the clinics were
weekly and the demands and resources required to roll out
such an intensive intervention would still be considerable.
Furthermore, it is unclear whether the diet or physical activity
components of combined lifestyle interventions contribute
most to an effect—which is important in order to guide the
investment of limited resources.
At present, it remains unclear whether real-world phys-
ical activity and/or dietary interventions can be successfully
integrated into the management of patients with T2D to
improve inflammation-associated cardiovascular risk. Early
ACTivity In Diabetes (ACTID) is a large study in people with
T2D that was designed to evaluate the effect of physical
activity over and above that of dietary intervention while
controlling for overall contact time with patients.14 The
physical activity component of Early ACTivity In Diabetes
(ACTID) was unsupervised and the intervention was
designed with roll out and implementation in mind.
Therefore, Early ACTivity In Diabetes (ACTID) represents a
unique opportunity to investigate the effect of diet and diet
plus physical activity on inflammation in a large trial in
patients with T2D who are at high risk of CVD.
Methods
Patients
Early ACTivity In Diabetes (ACTID) was a multicenter, parallel-
group, randomized, controlled trial. The study was approved
by the Bath Research Ethics Committee (05/Q2001/5), and
all participants provided written informed consent. This study
is registered (No. ISRCTN92162869) and has been described
in detail previously.14
In order to be eligible for Early ACTivity In Diabetes
(ACTID), patients had to have been diagnosed with T2D within
the previous 5 to 8 months and be older than 30 years at
diagnosis. Exclusion criteria were age older than 80 years,
glycated hemoglobin (HbA1c) concentration greater than 10%,
blood pressure higher than 180/100 mm Hg, low-density
lipoprotein (LDL) cholesterol concentration higher than
4 mmol/L, body-mass index lower than 25 kg/m2, mass
greater than 180 kg, use of weight-loss drugs, taking a
sulphonylurea at the maximum dose, unstable angina, a
myocardial infarction within the previous 3 months, inability
to increase physical activity, and pregnancy or planning to
become pregnant.14 The study was carried out in 5 secondary
care National Health Service (NHS) Trusts: Taunton and
Somerset NHS Foundation Trust; North Bristol NHS Trust;
Gloucestershire Hospitals NHS Trust; and Weston Area NHS
Trust. Recruitment was conducted between December 2005
and September 2008.
Recruitment and Randomization
Patients were recruited by searching the records databases of
217 general practices in southwest England. Eligible patients
had been diagnosed within the previous 5 to 8 months and
were older than 30 years at diagnosis. Patients were assigned
using a computer-generated allocation in a 2:5:5 ratio to usual
care, an intensive diet intervention, or the intensive diet
intervention plus activity. Allocation was stratified by center
and minimized by age, sex, fitness, route into the study, and
blood pressure. Dieticians, nurses, and patients were aware of
allocation, but doctors were not. All assessments were
performed by nurses.
Procedures
The usual-care arm was designed to serve as a control group
and consisted of standard dietary and exercise advice after
randomization, with reviews by a study doctor and nurse at
baseline as well as at 6 and 12 months.
The intensive diet intervention arm aimed to enable
patients to lose 5% to 10% of their initial body weight.14 The
diet was not prescriptive; goals were negotiated individually
with each participant. Participants saw a dietitian at 3, 6, 9,
and 12 months, and this contact was supplemented by
dietary advice and goal setting by nine 30-minute appoint-
ments with study nurses—approximately 1 every 6 weeks
over the course of the study.
Patients in the intensive diet and physical activity group
received the same dietary intervention as the intensive diet
group, but were also asked to undertake at least 30 minutes
of brisk walking on at least 5 days per week over and above
their existing physical activity. Each patient was given a
pedometer (Digi-Walker CW200; Yamax, Yamasa Tokei Keiki
Co., Ltd., Tokyo, Japan) and a folder containing motivating
literature and pages for recording daily physical activity
(pedometer readings). Activity targets were gradually
increased over 5 weeks and maintained for the remainder
of the study. Activity was discussed during the same nurse
appointments in order to keep the total contact time the same
as in the intensive diet intervention group.
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Clinical Management of Patients
Management of T2D, blood pressure, and lipid profile was
undertaken by the study team for the period of the trial. Any
changes in treatment of these features were made by a doctor
unaware of treatment allocation and according to a strict trial
protocol to keep the risk of performance bias to a minimum.
Diabetes treatment was only changed in the first 6 months if
fasting blood glucose concentration rose to more than
12.0 mmol/L, patients became symptomatic, or if blood
pressure was higher than 160/90 mm Hg at any visit. During
the second 6 months, patients were treated as appropriate to
maintain the following targets: HbA1c concentration lower
than 7.4%; blood pressure lower than 140/85 mm Hg;
total cholesterol concentration lower than 4.0 mmol/L;
high-density lipoprotein cholesterol concentration higher
than 1.0 mmol/L; LDL cholesterol concentration lower than
2.0 mmol/L, and concentration of triglycerides lower than
2.0 mmol/L.
Inflammatory Markers
Most previous studies have focused on CRP as a single
marker of inflammation, but there is uncertainty regarding the
extent with which CRP alone adequately captures the relevant
information on future risk.15 Increased hepatic secretion of
CRP is generally thought to be triggered by an increase in
systemic interleukin-6 (IL-6), with adipose tissue being a
particularly important source of IL-6.16 Increased adiposity is
also associated with lower serum concentrations of adipo-
nectin, and this adipokine has direct anti-inflammatory
effects.17,18 Thus, measurement of IL-6 and adiponectin
provide information on pro- and anti-inflammatory pathways
—which are heavily influenced by adipose tissue function. In
contrast, markers such as soluble adhesion molecules provide
information on inflammation within the vasculature, and such
measures independently predict the risk of CVD19 and stroke
in people with T2D.20 Thus, in the present study, we opted to
measure IL-6, adiponectin, and soluble intercellular adhesion
molecule-1 (sICAM-1) in addition to CRP. The vast majority of
samples from Early ACTivity In Diabetes (ACTID) were
available for inflammatory marker analysis, but, for logistical
reasons, some samples were unavailable.
Serum CRP was determined using an automated high-
sensitivity immunoturbidimetric assay and RX Daytona clinical
chemistry analyzer (Randox Laboratories Ltd., Crumlin, UK).
Serum was analyzed for IL-6, sICAM-1, and adiponectin using
commercially available solid-phase ELISAs (Quantikine; R&D
Systems Europe Ltd., Abingdon, UK). Average intra- and
interassay coefficient of variation (CV) was established from
the repeated analysis of 20 to 60 samples at different
concentrations. The intraassay CV was 3%, 5%, 6%, and 9% for
CRP, adiponectin, sICAM-1, and IL-6, respectively. The
interassay CV was 6 to 7% for all assays except IL-6, which
was 16%.
Statistical Analysis
Analysis of inflammatory outcomes at 6 months represents
the effect of the interventions without the confounding
complication of changes in medication, because this was
unadjusted during this period. Analysis of outcomes at
12 months provides a robust comparison with usual care,
because medication was adjusted to try and target predefined
clinical targets (see above). Given its role in risk prediction, we
examined the effect on CRP as both a continuous and
dichotomized variable (>3 versus ≤3 mg/L). For the contin-
uous variable model, we applied an ANCOVA (multiple
regression) model to adjust for the baseline value of CRP,
the minimization variables (age, sex, fitness, route into the
study, and blood pressure), and study center. Note that in the
first 6 months of Early ACTivity In Diabetes (ACTID), medica-
tion was not adjusted. For the dichotomized model, we used
generalized linear modeling to derive risk differences (bino-
mial distribution with an identity link) and risk ratios (binomial
distribution with a log link), adjusted for any chance
imbalance between groups at baseline for the proportion of
participants with a high-risk CRP value (>3 mg/L). Using the
risk differences, we obtained the number of participants
needed to treat (with the diet plus activity or diet interven-
tions versus usual care) for 1 additional participant to benefit
(NNTBENEFIT) as 1/the absolute risk reduction. Planned
comparisons were conducted between diet plus activity
versus usual care, diet versus usual care, and diet plus
activity versus diet, with no adjustment for multiple compar-
isons.21 The same analyses were conducted for CRP at the
12-month time point. The continuous variable analysis model
was adopted for the 6- and 12-month time points for the
secondary outcome variables (IL-6, s-ICAM-1, and adiponec-
tin). Mean effects are presented together with their 95%
confidence intervals (CIs). For the number needed to treat, a
CI crossing zero implies that the intervention might have a
harmful effect; in such cases, the CI was presented as
extending from the number needed to treat for 1 additional
participant to be harmed (NNTHARM) through infinity (absolute
risk reduction of zero) to NNTBENEFIT.
22 Continuous outcome
variables were natural log transformed before analysis.23
Resulting effects are therefore presented as percent (ratio)
differences between arms in change from baseline, derived
from back-transformation of the differences on the log scale.
Analysis of continuous outcomes was according to inten-
tion to treat using a full information maximum likelihood
method24 using the Stata (version 12.1; StataCorp, College
Station, TX) structural equation modeling (SEM) module. For
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the dichotomized CRP analysis, there was a small proportion
of cases with valid outcome data, but missing baseline data;
N=19 at 6 months and 17 at 12 months. These missing
baselines were imputed using a valid regression method.25
Both CRP and IL-6 can be influenced by acute infections, and
so we used a sensitivity analysis to explore whether excluding
high values (>10 or 20 mg/L for CRP and >10 pg/mL for IL-
6) influenced the outcome. Excluding samples with values
above these thresholds made no material difference to the
results, and so the data for all available samples are
presented. For the primary outcome (CRP at 6 months), we
conducted exploratory analyses to examine the extent to
which the intervention effects were moderated by sex,
baseline CRP level (continuous), and use of statins (yes/no).
Interactions between intervention arm and each of these
variables were added to the statistical model. All interaction
terms were entered simultaneously, rather than in separate
models, to avoid potential confounding, given that baseline
CRP levels were higher in women than in men and lower in
those on statins versus not, and a greater proportion of men
versus women were on statins. For baseline CRP level, we
determined the difference in intervention effect per 2-SD
increment.26 The effect of ethnicity could not be examined
robustly because >95% of the sample was of white European
origin. Because of the purely exploratory nature of these
secondary analyses, higher-order (3-way) interactions were
not examined.
For the 6-month time point, we examined the extent
(expressed as a percentage) to which the total observed
effects were mediated by 3 putative mechanism variables—
change in body mass, change in HbA1c, and change in
homeostasis model assessment of insulin resistance (HOMA-
IR). This mediation analysis was conducted using the Stata
software (SEM mediation module).
Results
Of 1634 patients who were screened by telephone, 593 were
enrolled into Early ACTivity In Diabetes (ACTID) and the
characteristics of each group were similar at baseline
(Table 1). Changes in HbA1c as well as measures of insulin
resistance (HOMA-IR) and weight were greater in both
intervention arms, compared to usual care, with no sub-
stantial difference between interventions.14 The diet plus
Table 1. Summary Statistics at Baseline
Diet (n=248) Diet Plus Activity (n=246) Usual Care (n=99)
Male sex N (%) 158 (64) 165 (66) 62 (63)
Age, y 60 (10) 60 (10) 60 (11)
Smoker N (%) 24 (10%) 16 (7%) 8 (8%)
White N (%) 239 (96%) 232 (94%) 96 (97%)
Median (IQR) time since diagnosis, days 186 (152 to 225) 194 (151 to 233) 185 (148 to 232)
Weight, kg 90.2 (16.7) 91.1 (16.9) 93.9 (19.0)
BMI, kg/m2 31.5 (5.7) 31.6 (5.6) 32.3 (5.9)
Diabetes medication N (%) 98 (40%) 95 (39%) 35 (35%)
Antihypertensive agents N (%) 168 (68%) 139 (57%) 58 (59%)
Lipid-lowering drugs N (%) 162 (65%) 150 (61%) 63 (64%)
HbA1c, % 6.64 (0.93) 6.69 (0.99) 6.72 (1.02)
HbA1c, mmol/mol 49 (10.2) 50 (10.8) 50 (11.1)
Systolic blood pressure, mmHg 133 (15) 133 (15) 135 (14)
Diastolic blood pressure, mmHg 79 (8) 79 (8) 80 (9)
Log HOMA-IR 1.60 (0.74) 1.65 (0.91) 1.62 (0.57)
CRP, mg/L* 2.0 (3.0) 2.0 (2.9) 2.3 (3.4)
IL-6, pg/mL* 2.0 (1.9) 2.0 (1.8) 2.4 (1.9)
sICAM-1, ng/mL* 249 (1.3) 242 (1.3) 255 (1.3)
Adiponectin, lg/mL* 5.0 (1.7) 4.8 (1.7) 5.0 (1.7)
Unless otherwise indicated, values represent means (SD). CRP indicates C-reactive protein; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance;
IL-6, interleukin-6; IQR, interquartile range; sICAM-1, soluble intercellular adhesion molecule-1.
*For inflammatory variables, the mean shown is the geometric mean, and the dispersion is the SD expressed as a factor (9/ by).
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activity group increased their mean daily step count from
6399 (3056) to 7680 (2818) and 7621 (2778) at 6 and
12 months, respectively. Approximately 90% of potential
blood samples were available for assessment of CRP, IL-6,
adiponectin, and sICAM-1 (Figure 1).
Impact of Interventions on Inflammatory Markers
Across Each Arm
Table 2 presents the effects of the interventions on CRP, IL-6,
s-ICAM-1, and adiponectin for each intervention arm and
analyzed as a continuous outcome. The general pattern of
results at 6 months is small, but clinically meaningful,
benefits of both interventions versus usual care (point
estimates 0.2 between-subject SDs). Beneficial changes in
CRP, sICAM-1, and adiponectin versus usual care were similar
in both intervention arms (Table 2). The magnitude of the
intervention effects in IL-6 was similar to the other markers,
but the CI reveals greater uncertainty for the population
effect.
Effects for CRP and adiponectin were attenuated at
12 months, but this was mainly the result of improvement in
the usual-care arm (Table 2). Indeed, between 6 and 12 months,
the adjusted mean values in the usual-care arm had improved by
23% for CRP and 3.2% for adiponectin. The effects on IL-6 and
sICAM-1 were similar at 12 versus 6 months.
Impact of Interventions on High-Risk CRP
The proportion of participants (SE) with a CRP >3 mg/L at
baseline was 44.4 (5.0)% for usual care, 37.1 (3.1)% for diet,
and 35.8 (3.1)% for diet plus activity, revealing a chance
imbalance. Using these baselines as a covariate in subse-
quent analysis of the dichotomized CRP variable (ie, high
versus low-to-moderate CRP) adjusted the intervention effects
appropriately to a common baseline proportion of a high-risk
CRP of 37.8%.
The proportion of participants with a high-risk CRP level at
6 and 12 months is shown in Figure 2. The risk differences at
6 months were 3.6 (95% CI, 12.2 to 5.1)% between diet
and usual care, 10.7 (19.6 to 1.7)% for diet plus activity
versus usual care, and 7.1 (14.4 to 0.2)% for diet plus
activity versus diet. The risk ratios for a high-risk CRP level at
6 months were 0.91 (0.72 to 1.15) for diet versus usual care,
0.72 (0.55 to 0.94) for diet plus activity versus usual care, and
0.79 (0.62 to 1.01) for diet plus activity versus diet. The
number needed to treat for benefit (versus usual care) at
6 months was 28 (NNTHARM 20 to ∞ to NNTBENEFIT 9)
participants for the diet intervention and 10 (5 to 77) with the
diet plus activity intervention.
At 12 months, the risk differences were 10.7 (20.0 to
1.4)% for diet versus usual care, 12.6 (22.2 to 3.0)%
for diet plus activity versus usual care, and 1.9 (9.5 to
5.6)% for diet plus activity versus diet. The risk ratios for a
high-risk CRP level at 12 months were 0.72 (0.55 to 0.95) for
diet versus usual care, 0.67 (0.50 to 0.90) for diet plus activity
versus usual care, and 0.93 (0.70 to 1.24) for diet plus activity
versus diet. The number needed to treat for benefit (versus
usual care) at 12 months was 10 (5 to 72) participants for the
diet intervention and 8 (5 to 34) with the diet plus activity
intervention.
Effect Moderation (Continuous Outcomes)
Exploratory analyses at the 6-month time point revealed a
tendency for the effect of the diet plus activity intervention to
be moderated substantially by sex, baseline CRP level, and
statin use. Changes in CRP level (versus usual care) tended to
be greater in men than women (ratio=0.66: 0.41 to 1.07),
greater per 2-SD increment in baseline CRP (ratio=0.76: 0.51
to 1.12), and greater in nonusers versus users of statins
(ratio=0.69: 0.44 to 1.09). Ratios less than 1 for these
interaction terms indicate larger beneficial reductions in CRP
from baseline versus usual care. For example, the ratio of
0.66 for the sex9diet plus activity group interaction,
described above, indicates that the ratio of mean CRP at
6 months in the diet plus activity group/usual care in men is
0.669 that in women; that is, there is a greater percent
reduction in CRP in men. The evidence for effect moderation
of the diet intervention was much weaker. The commensurate
ratios were 0.88 (0.55 to 1.42) for male/female, 0.97 (0.66 to
1.42) per 2-SD increment in baseline CRP, and 0.84 (0.53 to
1.33) for nonusers/users of statins. Note that the 95% CIs for
all interactions include the value of 1, indicating considerable
uncertainty in the estimation of the true population subgroup/
interaction effects.
At the 12-month time point for the diet plus activity
intervention, changes in CRP level (versus usual care) tended
to be larger in men than women (ratio=0.75: 0.46 to 1.22)
and larger in nonusers versus users of statins (ratio=0.72:
0.46 to 1.15). Changes in CRP level were significantly greater
per 2-SD increment in baseline CRP (ratio=0.61: 0.41 to
0.91). For the diet intervention, there was weaker evidence
for any possible effect moderation by sex or statin use, with
ratios of 1.07 (0.66 to 1.74) for male/female and 0.91 (0.57
to 1.45) for nonusers/users of statins. However, changes in
CRP level were significantly larger per 2-SD increment in
baseline CRP (ratio=0.67: 0.45 to 1.00).
Mediators of Effects on Continuous Outcome
Variables at 6 Months
The change in body mass mediated approximately 40% of
the total effect on CRP and over half of the total effect on
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Figure 1. CONSORT flow diagram showing participant and blood sample availability for the current study.
BMI indicates body mass index, BP, blood pressure.
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adiponectin (Table 3). The change in IL-6 had no
substantial mediating effect for the change in CRP (data
not shown).
Discussion
Our results show that motivational unsupervised diet and diet
plus physical activity interventions, integrated into healthcare
settings and with relatively modest resource implications,
generate beneficial changes in various inflammatory markers
in early T2D. Notably, even after adjustments to medication
were made to try and achieve predefined clinical targets, both
interventions were better than usual care for patients with a
higher risk of CVD (ie, with a CRP >3 mg/L) and for measures
of vascular risk (sICAM-1). There was no substantially greater
benefit from adding physical activity advice to dietary advice.
At 6 months, there was a similar mean reduction in CRP in
both interventions versus usual care of 21% to 22%. By
12 months, the effect on mean CRP level was substantially
attenuated, but the analysis of dichotomous high-risk CRP
revealed a substantial reduction in the risk of a high-risk CRP
value (>3 mg/L), with mean relative risk (RR) reductions of
28% for diet and 33% for diet plus physical activity and
numbers needed to treat for benefit of 10 and 8 participants,
respectively. As a corollary, the effect moderation analysis
Table 2. Adjusted Means for all Outcomes at 6 and 12 Months
Outcome Diet Diet Plus Activity Usual Care
Between-Arm Difference (95% Confidence Interval)
6 Months 12 Months
CRP, mg/L 6 months 1.71 1.69 2.18 — —
12 months 1.53 1.57 1.68 — —
Diet plus activity vs. UC 22 (38 to 3.4)% 6.5 (25 to 17)%
Diet vs. UC 21 (37 to 2.1)% 9.2 (27 to 13)%
Diet plus activity vs. diet 1.5 (17 to 16)% 3.1 (12 to 21)%
IL-6 (pg/mL) 6 months 1.95 2.01 2.17 — —
12 months 1.85 1.94 2.14 — —
Diet plus activity vs. UC 7.8 (19 to 4.4)% 9.3 (21 to 3.8)%
Diet vs. UC 10 (21 to 1.5)% 13 (24 to 0.9)%
Diet plus activity vs. diet 2.8 (6.3 to 13)% 4.7 (5.1 to 15)%
sICAM-1 (ng/mL) 6 months 234.3 233.2 247.2 — —
12 months 232.3 235.1 249.9 — —
Diet plus activity vs. UC 5.7 (9.6 to 1.5)% 5.9 (10 to 1.8)%
Diet vs. UC 5.2 (9.1 to 1.1)% 7.1 (11 to 3.1)%
Diet plus activity vs. diet 0.5 (3.7 to 2.8)% 1.2 (1.9 to 4.4)%
Adiponectin, lg/mL 6 months 5.76 5.68 5.33 — —
12 months 5.79 5.76 5.50 — —
Diet plus activity vs. UC 6.6 (0.8 to 13)% 4.7 (3.4 to 13)%
Diet vs. UC 8.1 (2.3 to 14)% 5.2 (2.8 to 14)%
Diet plus activity vs. diet 1.4 (5.5 to 2.8)% 0.6 (6.2 to 5.4)%
Geometric means are adjusted for the baseline value of the outcome, all minimization variables (age, sex, fitness, route into the study, and blood pressure), and study center. Adjusted
means are expressed with additional precision to better illustrate differences between geometric means expressed as a ratio. CRP indicates C-reactive protein; IL-6, interleukin-6; sICAM-1,
soluble intercellular adhesion molecule-1; UC, usual care.
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Figure 2. Proportion of patients with high-risk CRP >3 mg/L in
usual care (UC), diet, and diet plus physical activity (PA) arms at 6
and 12 months. Proportions have been adjusted to a mean
proportion at baseline of 37.8% to account for the chance imbalance
between groups (see text). CRP indicates C-reactive protein.
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shows that the effect of both interventions is substantially
greater (approximately 30% to 40% larger) in those with high-
risk CRP. Importantly, although the improvements experi-
enced by the usual-care arm attenuated the effect of both
interventions on mean CRP, usual care did not successfully
reduce the proportion of people with high-risk CRP (Figure 2).
Hence, both interventions were more successful than usual
care at substantially reducing the proportion of participants
with high-risk CRP.
In the usual-care arm, mean CRP improved between 6 and
12 months once medication was adjusted to try and ensure
that patients achieved predefined clinical targets. There was a
greater increase in diabetes medication use in the usual-care
arm between 6 and 12 months than in either intervention
arm,14 and diabetes medication, such as metformin, has an
established effect on inflammatory markers, such as CRP.27
Thus, for mean CRP at the whole-group level, conventional
treatment appears to catch up with diet and diet plus physical
activity advice when medication is adjusted according to fixed
protocols.14 However, as indicated above, this effect is not
equally distributed across the sample, and, notably, the
proportion of people in the usual-care arm with high-risk CRP
>3 mg/L was unchanged with usual care.
Weight loss was responsible for a substantial proportion of
the change in CRP in both intervention arms. Other large
intensive diet and physical activity interventions found that
weight loss was responsible for approximately half of the
change in CRP.13 Cross-sectional studies have shown that
adiposity, and not differences in physical activity, explain
variation in circulating markers of inflammation28,29 and that
plasma adipokines are disturbed in obese, but not nonobese,
patients with T2D.30 Furthermore, exercise without weight loss
does not change circulating concentrations of CRP.31–34 Thus,
although weight loss was relatively modest in both intervention
arms during the first 6 months of Early ACTivity In Diabetes
(ACTID), this explains much of the benefit in terms of changes
in CRP and this is consistent with previous studies. The
importance of weight loss for a change in CRP is interesting,
and further mechanistic studies are needed to better under-
stand the physiological processes underpinning this response.
Both interventions improved the other inflammatory mark-
ers (IL-6, sICAM-1, and adiponectin) after 6 months. As was
the case for CRP, the improvement in adiponectin in the usual-
care arm between 6 and 12 months meant that there were no
longer any substantial differences between interventions and
usual care at 12 months. This was not the case for sICAM-1,
which remained different in both intervention arms when
compared to usual care at 12 months. This finding for sICAM-1
is similar to the sustained changes in HbA1c, fasting insulin,
and fasting glucose reported previously.14 It is also noteworthy
that the change in weight was a less-important mediator of the
change in sICAM-1 than for CRP and adiponectin. Measure-
ment of sICAM-1 independently predicts the risk of CVD and
stroke in people with T2D.19,20 Thus, these results indicate that
diet and diet plus physical activity is more effective than
conventional treatment at targeting inflammatory markers
associated with vascular risk in patients with T2D.
There was some evidence that high-risk patients, as
defined by the American Heart Association (AHA),1 experi-
enced more-rapid changes in CRP in the diet plus physical
activity arm than the diet arm. The analysis of dichotomized
CRP values revealed a substantial benefit only for the diet plus
physical activity group after 6 months, with a mean RR
reduction for high-risk CRP level (>3 mg/L) of 21% (risk ratio
of 0.79) and a number needed to treat for benefit of 10
participants. However, by 12 months, physical activity had no
benefit over and above that of diet in terms of (1) mean CRP,
(2) proportion of patients with high-risk CRP, or (3) for any of
the other inflammatory markers. The lack of additional effect
from physical activity on inflammatory outcomes was surpris-
ing, but similar to that reported for other outcomes in Early
ACTivity In Diabetes (ACTID), such as HbA1c.14 Other studies
show that supervised exercise alone can have a much greater
effect on inflammatory markers than those reported in the
present study.9–12 However, Early ACTivity In Diabetes
(ACTID) was a pragmatic trial designed to test the benefit
from giving advice on physical activity in addition to diet in a
real-world, community-based setting in the first year after
diagnosis. Thus, these results show the effect from this
additional advice—and not the effect of physical activity per
se. This advice led to a statistically significant, but modest,
increase in physical activity.14 As a result of the energetics of
Table 3. Mediation of Total Effects at 6 Months by 3 Putative
Mechanism Variables
Outcome Δ Body Mass Δ Hba1c Δ HOMA-IR
CRP
Diet plus activity 40% 27% 28%
Diet 44% 22% 28%
IL-6
Diet plus activity 23% 4% 8%
Diet 18% 2% 6%
sICAM-1
Diet plus activity 27% 25% 29%
Diet 30% 21% 29%
Adiponectin
Diet plus activity 70% 24% 42%
Diet 59% 16% 33%
The percentage shown is the mean proportion of the total effect mediated by the
mechanism variable. CRP, C-reactive protein; HbA1c, glycated hemoglobin; HOMA-IR,
homeostatic model assessment of insulin resistance; sICAM-1, soluble intercellular
adhesion molecule-1.
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physical activity and other factors, such as substitution and
compensation, an ostensibly large change in a given behavior
might not translate into a large change in total activity energy
expenditure.35 Patients in the diet plus physical activity arm
increased their step count by 1300 steps per day.14 An
increase in physical activity of 1300 steps per day would
equate to walking 1000 m with an energy cost of 50 kcal
per day.36 Thus, our results show that this modest change in
physical activity has no additional benefit than dietary advice
on inflammatory markers and cardiovascular risk. Investing in
strategies to increase physical activity further might have
yielded greater improvements, but, of course, this is likely to
come with a greater financial cost.
One of the strengths of Early ACTivity In Diabetes (ACTID)
is that it purposefully targeted patients with newly diagnosed
T2D. Another strength is that there was no change in
medication over the first 6 months in order to better elucidate
the effect of lifestyle intervention. Though the changes in
inflammatory measures were small on average, this was
accomplished with a modest change to lifestyle that was
achieved without supervision, and, in particular, patients with
high-risk CRP, as defined by AHA, benefited from diet and
physical activity interventions.
There was an indication that the diet plus physical activity
intervention might be more effective in men and in those not
using statins. The latter finding is consistent with the effects
on CRP observed after an intensive lifestyle intervention in
which the intervention (versus control) tended to be more
effective in those not on statins.37
In conclusion, these results demonstrate that motivational,
unsupervised diet and diet plus physical activity interventions
integrated into real-world healthcare settings generate beneficial
changes in various markers of inflammation in patients with
newly diagnosed T2D. Importantly, unlike usual care, both
interventions reduced the proportion of patients with a high-risk
CRP. Furthermore, diet and diet plus physical activity advice were
more effective than usual care at improving sICAM-1, a marker of
vascular risk, even when medication was used to control blood
pressure, HbA1c, and lipids to agreed international targets.
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